Table 2.
Univariate and multivariate analysis for OS.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | Model 1 | Model 2 | |||
| HR (95% CI) | p value | HR (95% CI) | p value | |||
| Gender (male/female) | 2.091 (0.953–4.590) | 0.066 | 1.633 (0.718–3.713) | 0.242 | 1.669 (0.733–3.799) | 0.222 |
| ypTNM stage (0–I/II–III) | 0.321 (0.141–0.732) | 0.007 | 0.405 (0.174–0.945) | 0.037 | 0.420 (0.180–0.980) | 0.045 |
| Vascular invasion (absent/present) | 0.556 (0.170–1.821) | 0.332 | – | – | – | – |
| Lymphatic invasion (absent/present) | 0.400 (0.141–1.136) | 0.085 | 0.639 (0.208–1.959) | 0.433 | 0.721 (0.241–2.157) | 0.558 |
| Perineural invasion (absent/present) | 0.534 (0.250–1.141) | 0.105 | – | – | – | – |
| CRM (negative/positive) | 0.826 (0.198–3.449) | 0.826 | – | – | – | – |
| Pre-NCRT CEA (< 3.55/> 3.55) | 0.407 (0.185–0.893) | 0.025 | 0.506 (0.214–1.195) | 0.506 | 0.499 (0.212–1.173) | 0.111 |
| Pre-NCRT CA199 (< 19.0/> 19.0) | 0.437 (0.225–0.849) | 0.014 | 0.677 (0.322–1.422) | 0.303 | 0.632 (0.304–1.311) | 0.218 |
| Pre-NCRT NLR (< 2.565/> 2.565) | 0.355 (0.181–0.693) | 0.002 | 0.525 (0.244–1.131) | 0.100 | – | – |
| Pre-NCRT LMR (< 2.410/> 2.410) | 3.529 (1.702–7.319) | 0.001 | 2.239 (0.967–5.182) | 0.060 | – | – |
| NLM score (0–1/2) | 0.223 (0.108–0.464) | < 0.001 | – | – | 0.288 (0.134–0.619) | 0.001 |
Model 1: including Pre-NCRT NLR and LMR into multivariate analysis, not including NLM score. Model 2: including NLM score into multivariate analysis, not including Pre-NCRT NLR and LMR. NLR, neutrophil-to-lymphocyte ratio; LMR lymphocyte-to-monocytes ratio; NCRT, neoadjuvant chemoradiotherapy; Pre-NCRT NLR, NLR before patients receiving NCRT; Pre-NCRT LMR, LMR before patients receiving NCRT; CI, confidence interval.